Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.
about
Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malariaeditDihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malariaThe effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient dataAntimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertaintiesGametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient dataA head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trialDeclining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coastDihydroartemisinin-piperaquine vs. artemether-lumefantrine for first-line treatment of uncomplicated malaria in African children: a cost-effectiveness analysisEfficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquineMulti-Country Evaluation of Safety of Dihydroartemisinin/Piperaquine Post-Licensure in African Public Hospitals with ElectrocardiogramsCost analysis of school-based intermittent screening and treatment of malaria in KenyaThe impact of clinical research activities on communities in rural Africa: the development of the Clinical Research Unit of Nanoro (CRUN) in Burkina Faso.Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling.Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated falciparum Malaria Reduce the Risk for Recurrent New falciparum Infection More Than Artemether-Lumefantrine?Longitudinal study on Plasmodium falciparum gametocyte carriage following artemether-lumefantrine administration in a cohort of children aged 12-47 months living in Western Kenya, a high transmission areaTemporal association of acute hepatitis A and Plasmodium falciparum malaria in children.A review of the effects of artemether-lumefantrine on gametocyte carriage and disease transmissionIn vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in MozambiqueArtemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan childrenCost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania.Artemether-lumefantrine: an option for malaria.Changing malaria intervention coverage, transmission and hospitalization in Kenya.Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT intervalEffect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria.A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos.Malaria: an update on current chemotherapy.Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines.Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment.Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children.Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis.In vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso.Treating uncomplicated malaria in children: comparing artemisinin-based combination therapies.Effect of nutritional status on response to treatment with artemisinin-based combination therapy in young Ugandan children with malariaComparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic reviewPharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infantsComparative study of the efficacy and tolerability of dihydroartemisinin-piperaquine-trimethoprim versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal.Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model.Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites.Comparing the impact of artemisinin-based combination therapies on malaria transmission in sub-Saharan AfricaMass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination.
P2860
Q21032449-458CD1B7-F8FB-42DE-BB3D-D4D8295C6B74Q24201077-C72407B3-305A-4937-9FD6-A85FD7D9A191Q26822489-370BA2B8-FE1C-41C3-87E0-CFEF4E8E6510Q26866187-70D2ACC4-43BD-4C7C-A984-BF68D14CEBD6Q28068072-1937FDC5-7889-4116-9F38-354CE9EFFCCBQ28477853-A205045D-BD30-4893-BFDF-7B9E8EEE4EA8Q28477892-7FC0EDB5-ED54-43EA-8E5D-614A72FDA518Q28538065-577CFAA4-5D7F-45CC-A0CE-83B6FA556D65Q28542034-85A607D7-6E74-4B30-A63B-DBE985F628B4Q28552793-A08BC8A9-C64F-4B72-AFBA-1F0C18BC184BQ28744234-51B1FACD-B964-4B3E-B9DB-FEFF5DC86E34Q30391827-25F43D5A-5507-499A-95CF-44CA350AE5C0Q33678483-24974B10-E6C7-4246-B6B1-FA09A852B136Q33874069-7B54FAD4-1AC3-4EF1-BD1E-A20E8577721CQ33928116-67620D5F-AA95-47FD-9655-4988FCA356A4Q33960292-F29F97EC-C7FA-418F-A905-8C72CC988EF1Q34020818-A04622D5-AC8D-460B-8B72-AC2A62558AE5Q34042533-282F223B-61F6-4D68-9F3C-4F386DA2211AQ34137766-B2FC3820-FCE5-4235-BE06-94FE966F68CBQ34227179-A91CB4F5-31BC-4A3A-BE8C-34C25C93766BQ34267667-56DA8B66-EAA0-4A0A-8F1F-1CDEF4FFD40AQ34273825-916411F6-731B-4D82-AD82-9A3A86C17A8FQ34298973-6ED82457-49E6-432B-809D-8506F67778F2Q34299178-7ACC7AAE-21F9-4B79-ACD4-1D5466C71BB1Q34341784-6CF4CCFB-F1F3-4A06-AD8D-E8E462BB5235Q34433106-7B48C82F-198D-4FE8-AD4D-AE5E38DB8294Q34478487-912D7DF7-4BD1-49DD-944C-54EC6B8E55AEQ34629332-7B0721AB-9511-4E72-9542-5CFDEF0D4B17Q34662803-B3C36892-A430-4B50-9F57-8B42BEB91620Q34677891-CA8998C5-D660-4A51-9293-B6D57E5CA1AAQ34923315-74685B43-CC93-42A6-B735-4F345607A0DCQ35004430-5852ECAE-68DC-4561-94BD-6657E62BD722Q35004867-61A26985-2A81-4334-8B6B-B6831687D798Q35029488-69EB9E4E-B074-489E-85E8-A500E9F2CCEAQ35055212-3B575D2C-1867-4BFA-940E-BFD962798B7FQ35137471-2999DA95-4373-4B57-9887-451C1310FB02Q35139464-22E5FABF-30CB-4A80-8F5F-B52609C85D5BQ35139505-836E686D-D99B-4C64-934E-2705BD55763BQ35150299-90AEBAB4-9E0F-4A74-A227-4C228508D07BQ35224221-68002B05-78C9-41C2-8CF1-D1AAF25AA66E
P2860
Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Dihydroartemisinin-piperaquine ...... omised, non-inferiority trial.
@ast
Dihydroartemisinin-piperaquine ...... omised, non-inferiority trial.
@en
Dihydroartemisinin-piperaquine ...... omised, non-inferiority trial.
@nl
type
label
Dihydroartemisinin-piperaquine ...... omised, non-inferiority trial.
@ast
Dihydroartemisinin-piperaquine ...... omised, non-inferiority trial.
@en
Dihydroartemisinin-piperaquine ...... omised, non-inferiority trial.
@nl
prefLabel
Dihydroartemisinin-piperaquine ...... omised, non-inferiority trial.
@ast
Dihydroartemisinin-piperaquine ...... omised, non-inferiority trial.
@en
Dihydroartemisinin-piperaquine ...... omised, non-inferiority trial.
@nl
P2093
P2860
P50
P1433
P1476
Dihydroartemisinin-piperaquine ...... omised, non-inferiority trial.
@en
P2093
Ambrose Talisuna
Antonella Bacchieri
Carolyn Nabasumba
David Ubben
Innocent Valéa
Marco Corsi
Michael Nambozi
Modest Mulenga
Patrice Piola
Philip Sasi
P2860
P356
10.1371/JOURNAL.PONE.0007871
P407
P577
2009-11-17T00:00:00Z